Bicalutamida Plus Radiotherapy Extends Survival In Cancer Of Prostate

The third analysis of programme essay of cancer early prostate (EPC) new data confirm that antiandrogen bicalutamida dose of 150 mg, along with radiotherapy, extends deforms significant survival in men with locally advanced, compared with patients treated only with radiotherapy prostate cancer.

Bicalutamida (Casodex) is the only antiandrogen which has proved this fact. The EPC program is the largest clinical trial carried out on the treatment in men with prostate cancer early and shows that this prolongation of survival is independent of the initial treatment received by the patient.

It also confirms that this treatment significantly reduces the risk of bone metastasis in men with prostate cancer locally advanced compared to wait and see, and radical prostatectomy or radiation therapy only. Bone metastases are a symptom of disease progression and can accompany pain in bones and back which can hinder the walk and other everyday activities, and in more advanced cases can produce compression of the spinal cord.

To delay the progression of the disease, maintain your lifestyle and retain their physical and sexual activity are allowed to men with locally advanced prostate cancer. Commenting on these data, Professor Manfred Wirth, Department of Urology of the Technical University of Dresden (Germany), has stated: "the goal when handling this condition is a treatment that extend the life time and delay the advanced stage of the disease."

"The testing program EPC data suggest that bicalutamida 150 mg meets these vital needs and therefore benefit in men with locally advanced prostate cancer." This third analysis which has now been released adds clarity to the previous results and provides valuable insight on what group of patients with early disease benefits from the treatment.

In addition, the update of the "guidelines on cancer of prostate" of the European Association of Urology, recommends this as a good alternative to surgical castration or medical medicine for patients with advanced prostate cancer.

The programme of the essay EPC has followed 8.113 patients during a time average of 7.4 years in 23 different countries. The follow-up of patients will both continue to assess the progression of the disease as survival during a minimum period of 10 years since the last patient should be included in the study.



 

   

Try our free medication and pharmacy search engine! Just enter the name of the medication you are looking for (i.e. Phentermine, Vicodin, Xanax, Lortab, Valium, etc.). Listings are not verified by FindRxOnline.com and filtered from publicly available data. In addition to online pharmacies, searches may also provide other results. You must be 21 years or older to use this search engine.

Buy Discount Prescription Drugs from Online Consultation Services & Foreign Pharmacies